FibroScan®
Key Takeaways
1. FibroScan® Insights MASLD: FibroScan® is a non-invasive tool that provides liver stiffness measurement and liver steatosis quantification, offering insights beyond standard lab tests and imaging for better management of MASLD.
2. Predict Disease Progression: Liver fibrosis is a key prognostic feature in MASLD, and non-invasive tests like FibroScan® can predict disease progression and help in triaging patients for specialist care.
3. Assess Liver Health: The FibroScan® report includes liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) scores, which are crucial for assessing liver health and guiding treatment decisions.
4. Non-Invasive Selection: Emerging MASLD treatments may rely on non-invasive tests like FibroScan® for patient selection, with some guidelines already suggesting its use without the need for liver biopsy.
5. Annual Monitoring Tool: Regular monitoring with FibroScan®, typically recommended annually, can help track disease progression and treatment response, making it a valuable tool in ongoing patient management.
Why attend?
• Get a clear overview of Guided VCTE™ and how it enhances FibroScan® performance.
• Learn to interpret key parameters: Liver Stiffness Measurement (LSM), CAP™ (Controlled Attenuation Parameter), with the support of Fast and Agile Scores.
• Review real-world case studies in MASLD/MASH, from diagnosis to follow-up.
• Participate in a live Q&A session with expert answers to your clinical questions.
